Background It is estimated that 29.1 million people or 9.3% of the US population have
diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes …

The incretin system is an area of great interest for the development of new therapies for the
management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin-based therapies
for the management of hyperglycemia and, in some cases, cardiovascular risk in people with …

Type 2 diabetes mellitus is associated with progressive decreases in pancreatic β-cell
function. Most patients thus require increasingly intensive treatment, including oral …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated
257 million people worldwide. A number of unmet needs exist with traditional T2DM …

Novel therapeutic options for type 2 diabetes based on the action of the incretin hormone
glucagon-like peptide-1 (GLP-1) were introduced in 2005. Incretin-based therapies consist …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …